Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.5K
Clinical Trials01:16

Clinical Trials

9.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

265
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
265
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

263
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
263
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

270
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
270

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Scoping review of community-wide screening to break the chain of TB transmission.

IJTLD open·2026
Same author

Bedaquiline and levofloxacin replacing rifampicin for the treatment of TB.

IJTLD open·2025
Same author

Assessing the impact of the TB response in Taiwan - the journey towards ending TB.

IJTLD open·2025
Same author

A survey of the effectiveness of centralized consilia in providing advice on drug-resistant TB.

IJTLD open·2024
Same author

TB notifications among citizens and non-citizens in Taiwan.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

Armand Van Deun - pioneering public health physician (1953-2023).

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024

Related Experiment Video

Updated: Sep 28, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K

QT prolongation in the STREAM Stage 1 Trial.

G Hughes1, H Bern1, C-Y Chiang2

  • 1Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|March 30, 2022
PubMed
Summary

A shortened regimen for multidrug-resistant tuberculosis (MDR-TB) caused severe QT prolongation in one-third of patients. Risk factors included higher baseline QTcF and origin from Mongolia, impacting treatment implementation.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.4K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K

Related Experiment Videos

Last Updated: Sep 28, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.4K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • The Standardized Treatment Regimen of Anti-TB Drugs for Patients with MDR-TB (STREAM) Stage 1 trial showed a shortened regimen for rifampicin-resistant TB (RR-TB) was non-inferior in efficacy.
  • This shortened regimen includes moxifloxacin and clofazimine, drugs associated with QT prolongation, with severe prolongation observed more frequently than in the standard regimen.

Purpose of the Study:

  • To investigate risk factors associated with severe QT prolongation in patients receiving the shortened regimen for RR-TB.

Main Methods:

  • Analysis of data from 282 patients on the shortened regimen.
  • Identification of risk factors for severe QT prolongation, defined as QT/QTcF ≥500 ms or an increase of ≥60 ms from baseline.

Main Results:

  • 33.3% (94/282) of patients developed severe QT prolongation.
  • Severe QT prolongation (≥500 ms) was significantly more common in patients from Mongolia (45.5%) compared to other sites (3.5-11.9%).
  • A higher baseline QTcF (≥400 ms) was a significant risk factor for developing QT/QTcF ≥500 ms (OR 5.99).

Conclusions:

  • One-third of patients on the shortened RR-TB regimen experienced severe QT prolongation.
  • Geographic location (Mongolia) and higher baseline QTcF are key risk factors for severe QT prolongation.
  • Findings have implications for the clinical implementation and monitoring of this shortened TB treatment regimen.